Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

Board of Directors

Board of Directors

Jeffrey Albers

Venture Partner, Atlas Venture

Daniella Beckman

Chief Financial Officer, Tango Therapeutics

Alexis Borisy

Co-Founder and Operating Chairman, Curie.Bio

Lonnel Coats

Chief Executive Officer, Lexicon Pharmaceuticals

Habib Dable

Part-time Venture Partner, RA Capital Management, L.P.

Mark Goldberg, M.D.

Lecturer in Medicine, Harvard Medical School and Faculty Member, Hematology Division, Brigham and Women’s Hospital

Kate Haviland

President and Chief Executive Officer, Blueprint Medicines

Nick Lydon, Ph.D.

Scientific Founder, Blueprint Medicines

Lynn Seely, M.D.

President and Chief Executive Officer, Lyell Immunopharma and Lead Independent Director, Blueprint Medicines

John Tsai, M.D.

Chief Executive Officer, Forcefield Therapeutics